Evidence map›Paper›PMID 40296825›Full record

ArticleJournal of Korean medical science2025

Comprehensive Classification of Surgically Resected Pituitary Neuroendocrine Tumors: Updates From a Single-Institution Experience Based on the WHO 5th Edition.

Hyunhee Kim, Eric Eunshik Kim, Yong Hwy Kim, Jin Woo Park, Kyeong Cheon Jung, Haeryoung Kim, Jae Kyung Won, Sung-Hye Park

Abstract read
In one paragraph

Article in Journal of Korean medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hyunhee KimDepartment of Pathology, Samsung Medical Center, Sungkyunkwan University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0003-3353-1628
Eric Eunshik KimDepartment of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0001-5020-9150
Yong Hwy KimDepartment of Neurosurgery, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0001-9009-4191
Jin Woo ParkDepartment of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0003-0801-8208
Kyeong Cheon JungDepartment of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-7741-7184
Haeryoung KimDepartment of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-4205-9081
Jae Kyung WonDepartment of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0003-1459-8093
Sung-Hye ParkDepartment of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-8681-1597

Funding

Ministry of Health and Welfare RS-2023-00262321
6 · The paper itself

Abstract

backgroundThe 5th edition of WHO classification (WHO5) renamed pituitary adenoma as pituitary neuroendocrine tumor (PitNET), aligning with NET nomenclature from other sites. This study investigated the clinicopathological characteristics of surgically resected PitNET based on the WHO5 classification.

methodsA retrospective analysis was conducted on 210 cases of surgically resected and pathologically confirmed PitNET treated at Seoul National University Hospital from 2021 to 2023. The tumors were graded using the French five-tiered grading system proposed by Trouillas et al. Detailed information on grade 3 metastatic PitNET cases is provided.

resultsThe cohort's median age was 53 years (age range: 8-84 years), with a male-to-female ratio of 1:1.1. Mean tumor size was 2.5 cm (range: 0.1-6.5 cm). Macroadenomas predominated (91.9%), followed by microadenoma (6.7%), and giant tumors (1.4%), with 56.2% extending suprasellarly. SF1-lineage PitNET was most prevalent (49.5%), followed by PIT1-lineage (23.3%) and TPIT-lineage (17.1%). Null cell tumors (5.7%) and unclassified plurihormonal PitNET (4.3%) were rare. PIT1-lineage PitNET comprised somatotrophs (47.0%), mature plurihormonal PIT1 lineage tumors (18.4%), thyrotrophs (16.3%), immature PIT1-lineage tumors (16.3%), and acidophilic stem cell tumors (n=1), however, there was no lactotroph PitNET. Among SF1-lineage tumors, serologically non-functional tumors predominated (79%), while, immunohistochemically, 71.2% were gonadotrophin (FSH/LH)-positive. Tumor grades by the French five-tiered classification system were distributed as follows: grade 1a (58.1%), 1b (17.6%), 2a (16.2%), 2b (7.1%), and 3 (1.0%). Two cases of metastatic corticotroph PitNET were observed: The first case, a 50-year-old female had liver metastasis and experienced tumor recurrence 7 years after his initial diagnosis of PitNET, ultimately dying 9.5 years later. The primary tumor appeared bland, but the metastatic tumor exhibited a high mitotic rate and a Ki-67 index was 48%. The second case involved a 44-year-old man with metastases to the paranasal sinus, liver, and bone. Despite showing initial bland histopathology and a low proliferation index, this tumor displayed aggressive behavior. The patient had a recurrence 1.5 years after diagnosis, with additional metastases emerging 3 years later. He survived for 8.0 years and is currently disease-free following surgery, chemotherapy, and radiotherapy.

conclusionThis comprehensive analysis of surgically resected PitNETs using the new WHO5 classification provides valuable insights into the distribution of the subtypes in the surgical cohort. Key findings were the predominant gonadotroph PitNET, the absence of lactotroph PitNET, and the rarity of null cell tumors in surgical cases. The lack of lactotrophs was mainly due to medical treatment. This study highlights the discrepancy between serological and immunohistochemical findings of SF1-lineage PitNETs. While metastatic PitNET cases showed poor prognosis, the predictive value of the French grading system for PitNET requires further validation through extended follow-up.

Indexed as

Neuroendocrine TumorsPituitary NeoplasmsAdolescentAdultAgedAged, 80 and overChildFemaleHumansMaleMiddle AgedNeoplasm GradingRetrospective StudiesWorld Health OrganizationYoung AdultPituitary AdenomaPituitary Neuroendocrine TumorPituitary Transcription FactorsWHO Classifications

Identifiers

PMID40296825
PMCPMC12040610

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.